메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose This study was conducted to evaluate the treatment outcomes following definitive bimodalityconcurrent chemoradiotherapy (CCRT) in patients with inoperable N2-positive stage IIIA (N2-IIIA) non-small cell lung cancer (NSCLC). Materials and MethodsFrom May 1997 to December 2012, 65 out of 633 patients with N2-IIIA NSCLC receivedbimodality therapy. The treatment modality was selected during/after neoadjuvant CCRTin 21 patients or primarily at diagnosis in 44 through a multidisciplinary consensus meeting. The median age was 65 years (range, 36 to 76 years). Sixty patients (92.3%) had clinicallyevident N2 disease, while 22 (33.8%) had multi-station N2 involvement. The median radiationtherapy dose was 66 Gy in 33 fractions, while the dose was elevated to 72 Gy in 13patients who had a treatment break due to delayed decision regarding resectability. Themost frequent chemotherapy regimen was weekly paclitaxel or docetaxel plus cisplatin orcarboplatin (54, 83.1%). ResultsDuring the median follow-up of 18.8 months (range, 1.6 to 173.1 months), 34 patients(52.3%) experienced disease progression, with distant metastasis being the most commonfirst treatment failure pattern (23, 34.8%). The median and 2-year rates of progression-freesurvival were 18.8 months and 45.9%, respectively. The median and 2-year rates of overallsurvival were 28.6 months and 50.1%, respectively. ConclusionDefinitive bimodality therapy in patients with N2-IIIA NSCLC demonstrated favorable outcomes,while trimodality therapy could be considered for candidates for less than pneumonectomy.

목차

등록된 정보가 없습니다.

참고문헌 (17)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0